No Data
Pientzehuang Pharmaceutical's Q1 Attributable Profit Inches Up 3%
Zhangzhou Pientzehuang Pharmaceutical., Ltd Just Missed EPS By 5.7%: Here's What Analysts Think Will Happen Next
Pien Tsai: Report of the first quarter of 2025 of Zhangzhou Pien Tsai Pharmaceutical Co., Ltd.
Report for the first quarter of 2025 of Zhangzhou Pianziying Pharmaceutical Co., Ltd.
Announcement of the main operating data of Zhangzhou Pianziying Pharmaceutical Co., Ltd. for the first quarter of 2025
In the first quarter, revenue declined year-on-year. Is Zhangzhou Pientzehuang Pharmaceutical's "An Gong" not selling well? | Interpretations
In the first quarter, Zhangzhou Pientzehuang Pharmaceutical's revenue was 3.142 billion yuan, a year-on-year decrease of 0.92%, marking a decline for two consecutive quarters. The Net income attributable to shareholders of the listed company was 1 billion yuan, an increase of 2.59% year-on-year. The sales of the company's Angong Niuhuang Pill, a representative medication for cardiovascular and cerebrovascular diseases, saw a decline of over 80%.
102884128 : getting disappointed with this counter. every day drop.